VCYT — Veracyte, Inc. stock price, charts and financials

NASDAQ·Healthcare·Medical - Diagnostics & Research·USA

Latest market price

39.80

-0.77-1.90%

Overview Short InterestFilings

VCYTQT59Veracyte, Inc.·NASDAQ

Overview Short InterestFilings

39.80-1.90%

News

Down 1.9% — Waters Launches BD FACSDiscover A7 for Advanced Flow Cytometry (Yahoo).

Medium confidence

Loading chart...

Signal & projected range

Insider open-market saleHistorical pattern — not a prediction

Recent priceDays this stock last showed the setupRange of past outcomes (±1σ)

Horizon

Unlock the projected rangeSee where this setup landed historically — with Premium.

Unlock with Premium

Over the next 20 trading days, similar setups historically landed in a measured range of outcomes. Unlock with Premium to see the median return, the typical range, and how often they were positive. This is the historical range of outcomes — not a prediction of this stock’s price.

Ranges describe how this exact setup resolved in the past — derived from thousands of historical occurrences across QuoTrend’s coverage since 2006, survivorship-corrected to include companies that later delisted. The band is the typical spread (±1σ) of those outcomes, not a forecast; the central value is their average move. Fewer matching cases over longer horizons widen the band and lower its reliability. Backtested results are hypothetical, based on historical data, and do not represent actual trading. Past performance does not guarantee or predict future results. QuoTrend is an educational research tool, not investment advice. Markets involve risk, including loss of principal.

Screen all →

GRAL+1.03%$80.77 CDNA-0.83%$53.83 BLLN-4.29%$105.92 WGS-3.67%$101.10 SHC-1.16%$18.73 PSNL+1.05%$16.40 RDNT-2.29%$76.00 OPK+3.09%$1.67

Snapshot

Index	-	P/E	27.64	EPS (ttm)	1.44	Insider Own	2.78%	Shs Outstand	79.79M	Perf Week	-2.62%

Market Cap	3.18B	Forward P/E	20.40	EPS next Y	1.95	Insider Trans	-10.55%	Shs Float	79.87M	Perf Month	-5.66%

Enterprise Value	2.92B	PEG	0.09	EPS next Q	0.43	Inst Own	-	Short Float	10.11%	Perf Quarter	-25.79%

Income	114.63M	P/S	5.65	EPS this Y	36.72%	Inst Trans	-	Short Ratio	5.91	Perf Half Y	21.42%

Sales	561.90M	P/B	2.28	EPS next Y	1.94%	ROA	7.70%	Short Interest	8.08M	Perf YTD	-5.46%

Book/sh	-	P/C	17.77	EPS next 5Y	5.60%	ROE	8.64%	52W High	60.91 -34.66%	Perf Year	25.04%

Cash/sh	-	P/FCF	19.19	EPS past 3/5Y	-	ROIC	6.70%	52W Low	29.46 35.10%	Perf 3Y	57.00%

Dividend Est.	-	EV/EBITDA	22.47	Sales past 3/5Y	20.29% 34.60%	Gross Margin	72.09%	Volatility	5.35% 4.37%	Perf 5Y	-18.21%

Dividend TTM	-	EV/Sales	5.19	EPS Y/Y TTM	351.61%	Oper. Margin	17.03%	ATR (14)	2.15	Perf 10Y	490.50%

Dividend Ex-Date	-	Quick Ratio	8.80	Sales Y/Y TTM	26.01%	Profit Margin	20.37%	RSI (14)	39.09	Recom	2.36

Dividend Gr. 3/5Y	-	Current Ratio	9.16	EPS Q/Q	22.73%	SMA20	-6.22%	Beta	1.95	Target Price	57.43

Payout	0.00%	Debt/Eq	0.03	Sales Q/Q	15.38%	SMA50	-16.35%	Rel Volume	2.03	Prev Close	40.57

Employees	755	LT Debt/Eq	0.03	Earnings	Nov 03	SMA200	-6.33%	Avg Volume	1.31M	Price	39.80

IPO Date	Oct 29, 2013	Option/Short	Yes / Yes	EPS/Sales Surpr.	31.62% 3.96%	Net Debt/EBITDA	-2.00	Volume	2,667,593	Change	-1.90%

Analyst Ratings

Date	Action	Analyst	Rating	Target
Sep-09-26	Reiterated	UBS	Buy	$52 → $65
Aug-04-26	Reiterated	Piper Sandler	Overweight	$66 → $54
Aug-04-26	Reiterated	Stephens & Co.	Overweight	$55
Aug-04-26	Reiterated	Morgan Stanley	Underweight	$47 → $44
Aug-03-26	Reiterated	Canaccord Genuity	Hold	$60 → $50
Jul-31-26	Reiterated	Needham	Buy	$57 → $69
Jul-30-26	Reiterated	Needham	Buy	$57 → $69
Jul-15-26	Reiterated	Piper Sandler	Overweight	$66
Jul-14-26	Reiterated	Canaccord Genuity	Hold	$42 → $60
Jul-09-26	Reiterated	Morgan Stanley	Underweight	$37 → $47

Latest News· Times ET

Sep-18-26

Sep-18-2610:35AM

Waters Launches BD FACSDiscover A7 for Advanced Flow CytometryYahoo

Sep-16-26

Sep-16-2611:30PM

Corient Private Wealth LP Has $9.52 Million Holdings in Veracyte, Inc. $VCYTdefenseworld.net

Sep-15-26

Sep-15-2606:31AM

Veracyte, Inc. (VCYT) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcriptseekingalpha.com

Sep-14-26

Sep-14-2612:05PM

Veracyte Acquires Convergent Genomics, Expanding its Urology Diagnostics Portfolio with a Urinary Tumor DNA Testing Platformglobenewswire.com

Sep-11-26

Sep-11-2611:37PM

Concurrent Investment Advisors LLC Takes Position in Veracyte, Inc. $VCYTdefenseworld.net

Sep-10-26

Sep-10-2612:57PM

Here's Why You Should Retain Ecolab Stock in Your Portfolio NowYahoo

Sep-09-26

Sep-09-2603:49PM

Veracyte Inc (VCYT) Shares Surge 3.3% -- What GF Score of 81 Tells Investorsgurufocus.com

06:06AM

3 Medical Instruments Stocks Banking on GenAI to Tackle Industry Woeszacks.com

Sep-04-26

Sep-04-2603:39PM

Here's Why You Should Retain Cencora Stock in Your Portfolio for NowYahoo

Sep-01-26

Sep-01-2612:05PM

Veracyte to Participate in the Morgan Stanley 24th Annual Global Healthcare Conferenceglobenewswire.com

12:03AM

Canada Pension Plan Investment Board Purchases Shares of 20,700 Veracyte, Inc. $VCYTdefenseworld.net

Aug-30-26

Aug-30-2612:24AM

Connor Clark & Lunn Investment Management Ltd. Takes $1.58 Million Position in Veracyte, Inc. $VCYTdefenseworld.net

Aug-26-26

Aug-26-2611:39PM

Bamco Inc. NY Invests $38.22 Million in Veracyte, Inc. $VCYTdefenseworld.net

07:20AM

Is it Worth Adding Veracyte Stock to Your Portfolio Now?zacks.com

Aug-25-26

Aug-25-2607:26AM

VCYT Drops 25.3% in the Past Month. Is the Sell-Off an Opportunity?zacks.com

Company

Veracyte, Inc. operates as a diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier for cancerous thyroid nodules; Decipher Prostate Genomic Classifiers for prostate cancer diagnosis; Decipher Bladder Genomic Classifier for bladder cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; and Percepta Nasal Swab Test for lung cancer diagnosis. It also provides the nCounter analysis system services. The company was formerly known as Calderome, Inc. and changed its name to Veracyte, Inc. in March 2008. Veracyte, Inc. was incorporated in 2006 and is headquartered in South San Francisco, California.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements

DataTimeframe

Line Item (USD, M)	TTM —	FY 2025 12/31/2025	FY 2024 12/31/2024	FY 2023 12/31/2023	FY 2022 12/31/2022	FY 2021 12/31/2021	FY 2020 12/31/2020	FY 2019 12/31/2019	FY 2018 12/31/2018
Total Revenue	562	517	446	—	—	—	—	—	—
Cost of Goods Sold Incl. D&A	157	157	148	—	—	—	—	—	—
Gross Profit	406	360	298	—	—	—	—	—	—
Selling, General and Administrative Excl. Other	202	211	206	—	—	—	—	—	—
Research and Development	93	71	69	—	—	—	—	—	—
Other Operating Expense	15	4	7	—	—	—	—	—	—
Operating Income	96	74	16	—	—	—	—	—	—
Interest Expense	0	0	0	—	—	—	—	—	—
Unusual Expense	—	—	—	—	—	—	—	—	—
Non-Operating Income (Expense)	13	-6	10	—	—	—	—	—	—
Net Income Before Taxes	109	68	26	—	—	—	—	—	—
Income Taxes	-6	2	2	—	—	—	—	—	—
Consolidated Net Income	114	66	24	—	—	—	—	—	—
Net Income From Continuing Operations	114	66	24	—	—	—	—	—	—
Net Income	114	66	24	—	—	—	—	—	—
EPS (Recurring)	1.44	0.84	0.32	—	—	—	—	—	—
EPS (Basic, Before Extraordinaries)	1.44	0.84	0.32	—	—	—	—	—	—
EPS (Diluted)	1.40	0.82	0.31	—	—	—	—	—	—
EBITDA	129	90	49	—	—	—	—	—	—
Other After Tax Adjustments	—	—	—	—	—	—	—	—	—
Stock Option Compensation Expense	—	—	—	—	—	—	—	—	—
Price To Earnings Ratio	28.43	51.34	127.74	—	—	—	—	—	—
Price To Sales Ratio	5.67	6.43	6.75	—	—	—	—	—	—
Gross Margin	72.24	69.63	66.82	—	—	—	—	—	—
Operating Margin	17.08	14.31	3.59	—	—	—	—	—	—
Net Margin	20.28	12.77	5.38	—	—	—	—	—	—
Shares Outstanding	80	79	76	—	—	—	—	—	—
Market Capitalization	3,184	3,326	3,010	—	—	—	—	—	—
Operating Lease Expense	—	—	—	—	—	—	—	—	—

Unlock full historical data

See years of past statements with Premium.

Unlock with Premium

Insider Trading Volume

Insider Trading

Insider	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Holstein Jens	Director	Sep 14 '26	Sale	40.95	5,000	204,747	27,471	Sep 16
Febbo Phillip G.	Chief Scientific & Med Officer	Sep 04 '26	Sale	43.05	13,110	564,410	133,048	Sep 04
Chambers Rebecca	Chief Financial Officer	Sep 04 '26	Sale	43.10	3,652	157,394	166,025	Sep 04
McGuire Annie	EVP, General Counsel	Sep 04 '26	Sale	43.09	3,254	140,212	131,160	Sep 04
Bhanji Muna	Director	Sep 01 '26	Sale	42.97	1,864	80,096	42,718	Sep 03
EASTHAM KARIN	Director	Jun 18 '26	Sale	52.89	3,729	197,234	15,097	Jun 22
McGuire Annie	EVP, General Counsel	Jun 04 '26	Sale	49.76	3,176	158,036	137,240	Jun 04
Stapley Marc	Chief Executive Officer	Jun 04 '26	Option Exercise	36.60	138,051	5,052,667	578,545	Jun 04
Stapley Marc	Chief Executive Officer	Jun 04 '26	Sale	50.12	138,051	6,919,585	440,494	Jun 04
Chambers Rebecca	Chief Financial Officer	Jun 04 '26	Sale	49.73	3,561	177,083	173,280	Jun 04
Leite John	Global Chief Commercial Off	Jun 04 '26	Sale	50.07	13,975	699,732	132,305	Jun 04
Wygant Jonathan	VP, Chief Accounting Officer	May 22 '26	Option Exercise	24.80	24,000	595,200	69,434	May 27
Wygant Jonathan	VP, Chief Accounting Officer	May 22 '26	Sale	45.40	24,000	1,089,624	45,434	May 27
EPSTEIN ROBERT S	Director	May 20 '26	Sale	44.01	10,000	440,129	52,446	May 22
McGuire Annie	SVP, General Counsel	May 06 '26	Sale	39.02	10,204	398,211	143,708	May 08

open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR

QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.